Akero Therapeutics, Inc. (FRA:0K4)
46.70
+0.04 (0.09%)
At close: Nov 28, 2025
Akero Therapeutics Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2017 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2017 - 2019 |
Cash & Equivalents | 176.03 | 340.24 | 234.21 | 249.77 | 150.48 | 187.24 | Upgrade |
Short-Term Investments | 561.79 | 402.84 | 315.8 | 101.68 | 37.78 | 81.15 | Upgrade |
Cash & Short-Term Investments | 737.83 | 743.08 | 550.01 | 351.45 | 188.26 | 268.39 | Upgrade |
Cash Growth | 2.87% | 35.10% | 56.50% | 86.69% | -29.86% | 96.77% | Upgrade |
Prepaid Expenses | 16.71 | 27.3 | 9.95 | 3.72 | 5.32 | 2.96 | Upgrade |
Total Current Assets | 754.54 | 770.38 | 559.96 | 355.17 | 193.58 | 271.35 | Upgrade |
Property, Plant & Equipment | 0.55 | 0.76 | 1.03 | 1.29 | 1.55 | 1.79 | Upgrade |
Long-Term Investments | 250.49 | 54.75 | 19.28 | - | - | - | Upgrade |
Other Long-Term Assets | - | - | - | 0.11 | 0.42 | 0.2 | Upgrade |
Total Assets | 1,006 | 825.89 | 580.27 | 356.57 | 195.55 | 273.34 | Upgrade |
Accounts Payable | 20.4 | 9.03 | 7.04 | 7.97 | 6.71 | 3.43 | Upgrade |
Accrued Expenses | 26.38 | 30.1 | 11.57 | 10.79 | 18.22 | 9.39 | Upgrade |
Current Portion of Leases | 0.32 | 0.29 | 0.52 | 0.33 | 0.21 | 0.29 | Upgrade |
Other Current Liabilities | 0.56 | 0.34 | - | - | - | - | Upgrade |
Total Current Liabilities | 47.65 | 39.75 | 19.13 | 19.08 | 25.13 | 13.11 | Upgrade |
Long-Term Debt | - | 35.3 | 24.96 | 9.54 | - | - | Upgrade |
Long-Term Leases | 0.29 | 0.53 | 0.82 | 1.08 | 1.31 | 1.52 | Upgrade |
Other Long-Term Liabilities | - | 0.19 | 0.05 | 0.31 | - | - | Upgrade |
Total Liabilities | 47.94 | 75.77 | 44.97 | 30.01 | 26.44 | 14.63 | Upgrade |
Common Stock | 0.01 | 0.01 | 0.01 | 0.01 | 0 | 0 | Upgrade |
Additional Paid-In Capital | 2,005 | 1,575 | 1,109 | 748.86 | 479.44 | 468.24 | Upgrade |
Retained Earnings | -1,049 | -826.16 | -574.1 | -422.34 | -310.3 | -209.53 | Upgrade |
Comprehensive Income & Other | 1.83 | 0.95 | 0.27 | 0.04 | -0.03 | -0 | Upgrade |
Total Common Equity | 957.64 | 750.11 | 535.31 | 326.56 | 169.11 | 258.71 | Upgrade |
Shareholders' Equity | 957.64 | 750.11 | 535.31 | 326.56 | 169.11 | 258.71 | Upgrade |
Total Liabilities & Equity | 1,006 | 825.89 | 580.27 | 356.57 | 195.55 | 273.34 | Upgrade |
Total Debt | 0.61 | 36.12 | 26.31 | 10.95 | 1.52 | 1.81 | Upgrade |
Net Cash (Debt) | 987.71 | 761.71 | 542.99 | 340.5 | 186.74 | 266.58 | Upgrade |
Net Cash Growth | 31.51% | 40.28% | 59.47% | 82.34% | -29.95% | 95.56% | Upgrade |
Net Cash Per Share | 12.62 | 11.35 | 10.33 | 8.73 | 5.36 | 8.47 | Upgrade |
Filing Date Shares Outstanding | 82.32 | 79.62 | 56.3 | 46.97 | 35.01 | 34.77 | Upgrade |
Total Common Shares Outstanding | 80.15 | 72.38 | 55.75 | 46.87 | 34.9 | 34.74 | Upgrade |
Working Capital | 706.88 | 730.63 | 540.83 | 336.09 | 168.45 | 258.23 | Upgrade |
Book Value Per Share | 11.95 | 10.36 | 9.60 | 6.97 | 4.85 | 7.45 | Upgrade |
Tangible Book Value | 957.64 | 750.11 | 535.31 | 326.56 | 169.11 | 258.71 | Upgrade |
Tangible Book Value Per Share | 11.95 | 10.36 | 9.60 | 6.97 | 4.85 | 7.45 | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.